期刊文献+

造血干细胞移植共患病指数对异基因造血干细胞移植后非复发死亡率及总生存率的预测作用 被引量:1

Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after aUogeneic hematopoietic stem cell transplantation
原文传递
导出
摘要 目的探讨造血干细胞移植共患病指数(HCT-CI)对异基因造血干细胞移植(allo-HSCT)患者移植后非复发死亡率(NRM)及总生存(OS)率的预测作用。方法选取2003年7月至2010年11月allo—HSCT患者161例纳入研究队列随访并总结临床资料,多因素分析HCT-CI、患者年龄、性别、预处理方案、移植前疾病状态、移植方式、HLA配型对NRM及OS率的影响。分析在不同移植前疾病状态下,HCT-CI评分对OS率及NRM的预测作用。结果161例allo-HSCT患者3年OS率及NRM分别为61.4%及26.4%。HCT-CI评分0分、1-2分及I〉3分组患者的3年NRM分别为14.9%、24.5%、52.7%,3年OS率分别为68.9%、64.6%、34.7%。组间比较显示,HCT-CI评分I〉3分和0分组患者的3年NRM及OS率差异有统计学意义(P值均〈0.01)。COX回归模型分析显示,移植前疾病状态高危、HCT-CI评分〉13为影响OS率及NRM的独立危险因素(相对危险度分别为3.53和3.35,3.77和6.85,P值均〈0.01)。在移植前疾病状态为低危的101例患者中,HCT-CI评分为0分、1-2分和I〉3分组患者的3年NRM及OS率差异有统计学意义(P值均〈0.01);而在高危组的60例患者中,不同HCT-CI评分组间OS率及NRM的差异无统计学意义(P=0.252及0.347)。结论HCT-CI评分及移植前疾病状态分层是影响allo-HSCT后NRM和OS率的独立危险因素。在移植前疾病状态低危组,HCT-CI评分对allo-HSCT移植后的NRM及OS率具有预测作用;在移植前疾病状态高危组,HCT-CI评分对NRM及OS率无预测作用。 Objective To study the prognostic implications of hematopoietic cell transplantationspecific comorbidity index (HCT-CI) on non-relapse mortality (NRM) and overall survival (OS) in patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Clinical data of 161 cases received allo-HSCT from July 2003 to November 2010 were analyzed retrospectively. The prognostic significance of HCT-CI, age, sex, conditioning regimens, disease status before transplantation, graft source and the degree of HLA matches for NRM and OS was conducted by COX regression model. The prognostic impact of HCT-CI on NRM and OS was performed in all patients under different disease status before transplantation. Results Of the 161 cases with allo-HSCT, 3-year NRM and OS were 26.4% and 61.4% respectively. NRM at 3 years in patients with HCT-CI score 0, 1-2 and ≥3 were 14.9% , 24.5% and 52.7% respectively. And OS at 3 years were 68.9% , 64.6% and 34.7% respectively. There were significant differences between HCT-CI score 0 and≥3 groups for NRM and OS (P〈0.01). High-risk disease status before transplantation (NRM: RR=3.35, P〈0.01; OS: RR=3.53, P〈 0.01) and HCT-CI score≥3 (NRM: RR=6.85, P〈0.01; OS: RR=3.77, P〈0.01) were independent risk factors by COX regression model. In the subgroup analysis according to disease status, high score of HCT- CI was associated with poor OS (P〈0.01) and high NRM (P〈0.01) in patients with low-risk, but not in those with high-risk disease status. Conclusions HCT-CI score and disease status before transplantation are independent risk factors for patients received allo-HSCT. HCT-CI score have prognostic implication for NRM and OS in patients with low-risk disease status, but not in high-risk group.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2013年第8期659-663,共5页 Chinese Journal of Hematology
基金 卫生公益性行业科研专项(201202017) 国家科技支撑计划(2008BA161801) 北京市科委首都市民健康项目培育(Z111107067311070)
关键词 造血干细胞移植 共患病指数 共患病 疾病状态 Hematopoietic stem cell transplantation Comorbidity index Non-relapse mortality Overall survival
  • 相关文献

参考文献10

  • 1何军,徐超,吴小津,鲍晓晶,邱桥成,袁晓妮,李杨,沈宏杰,吴德沛,洪峻岭,刘静湖,杜海英,张雷,杜丹,鲁静,柳静.供受者HLA高分辨基因分型不合对非血缘造血干细胞移植患者预后的影响[J].中华血液学杂志,2012,33(5):353-357. 被引量:11
  • 2胡炯,章卫平,杨丹,唐暐,宋献民,王玲,赵维莅,吴文,王健民.EBMT积分在异基因造血干细胞移植治疗慢性粒细胞白血病中的预后价值[J].中华血液学杂志,2011,32(2):75-78. 被引量:5
  • 3Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 2005, 106: 2912-2919.
  • 4Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among pa.tients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.J Clin Oncol, 2007, 25: 4246-4254.
  • 5Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predic.tor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood, 2007, 11 0:4606-4613.
  • 6Sorror ML, Storer BE, Maloney DO, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmye.loablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood, 2008, 111: 446-452.
  • 7Sorror M, Storer B, Sandmaier BM, et al.Hematopoietic cell transplantation- comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplan.tation.Cancer, 2008, 112: 1992-2001.
  • 8Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical out.comes in lymphoma and myeloma patients after reduced-intensi.ty or non- myeloablative allogeneic stem cell transplantation. Leukemia, 2009, 23:1131-1138.
  • 9WHO Expert Consultation. Appropriate body- mass index for Asian populations and its implications for policy and interven.tion strategies. Lancet, 2004, 363: 157-163.
  • 10Kataoka K, Nannya Y, Veda K, et al. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a singleJapanese trans.plant centre study. Bone Marrow Transplant, 2010,45: 513-520.

二级参考文献13

  • 1Hurley CK. Guidelines for selection of unrelated adult volunteer donors for hematopoietic progenitor cell transplantation. ASHI, 2011, 4: 2-7.
  • 2Lee S J, Klein J, Haagenson M, et al. High-resolution donor-re- cipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood ,2007, 110 : 4576-4583.
  • 3Woolfrey A, Klein JP, Haagenson M, et al. HLA-C antigen mis- match is associated with worse outcome in unrelated donor periph- eral blood stem cell transplantation. Biol Blood Marrow Trans- plant, 2011,17:885-892.
  • 4Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus- host disease and implication for its molecular mechanism. Blood, 2007,110 : 2235-2241.
  • 5Kawase T, Matsuo K, Kashiwase K, et al. HLA mismatch combi- nations associated with decreased risk of relapse implications for the molecular mechanism. Blood, 2009,1 ! 3 : 2851-2858.
  • 6Park M, Koh KN, Kim BE,et al. The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children. Korean J Hematol,2011,46 : 11-17.
  • 7He J, Li Y, Bao X,et al. Common and well-documented (CWD) alleles of human leukocyte antigen-A, B, C, DRBl,and-DQB1 loci for the Chinese Han population do not quite correlate with the ASHI CWI) alleles. Hum Immunol, 2012, 73: 61-66.
  • 8Yagasaki H, Kojima S, Yabe H, et al. Acceptable HLA-mismatc- hing in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood, 2011, 118: 3186- 3190.
  • 9Ciurea SO, Saliba RM, Rondon G, et al. Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant,2011, 17 : 923 -929.
  • 10Michallet M, Sobh M, Milligan D, et al. The impact of HLA matching on long-term transplant outcome after allogeneic hema- topoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia, 2010, 24 : 1725-1731.

共引文献14

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部